Gilead Sciences Inc. (NASDAQ: GILD), has a current market cap of 159.7B and has seen over the past 3 months 10675900 shares traded hands on daily basis at $123.62. The standard deviation of short term price target has been estimated at $15.01, implying that the actual price may vary this value. CEO John Martin indirectly has ownership of 0 shares. Usually insider selling means a bearish sign.
Martin sold 133,213 shares of the business’s stock in a transaction on Tuesday. These professional stockholders lowered the total shares they own by 47.10 million to 1.23 billion this quarter.
The experts say
The American multinational financial services corporation, Morgan Stanley, increased the target price on shares of Gilead Sciences from $125.00 to $127.00. Next year’s EPS price will be of 9.35. Usually, a rating under 2 means to buy, while if it is within the range of 3 then it is recommended to hold it instead.
Currently company insiders own 0.5% of Gilead Sciences. Bank of America later released a report in May 8, reaffirming an “underperform” rating on shares of Gilead sciences. It has decreased by 14% since then. Its growth is 54.20% year over year (YOY). Around 23% of the company’s shares are short sold. There were 101 funds that closed their positions and 487 that reduced them.
Moreover, 190 registered investment advisors are confident in the stock and have it in their Top 10. Gilead Sciences Inc. (GILD) has a price to earnings ratio of 11.12 versus Healthcare sector average of 40.26.
Investors often turn to Wall Street analysts to help determine the direction of a stock. Cubist Systematic Strategies Llc has 0.80% of their stock portfolio invested in the stock for 157,832 shares. Around 2% of the company’s shares, which are float, are short sold. The sell-side is extremely optimistic on Gilead stock.
Gilead Sciences was the stock of the day practically 1 year ago.
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that develops and commercializes innovative medicines. The company’s main focus includes: liver diseases including chronic hepatitis C virus (HCV), disease and persistent hepatitis B virus (HBV) infection, oncology and inflammation, cardiovascular and respiratory ailments, and human immunodeficiency virus (HIV).